Thanks for publishing this article which is very beneficial for all of us.Keep it up.

an interest in purchasing STAGO....or, are they not yet done with acquisitions?

IRIS originally had a synergistic agreement with Arkray to provide the urine dipstick reader for their IQ200 system. I'm not sure what cau tony

52 week high 57.15 now 56 50 do you need glasses?

Danaher Stock Hits New 52-Week High (DHR)...They must be doing something right!!!???

"Crisis for 40000 employees. not for the top management, and their lifestyles"

Welcome to DHR. Screw or be screwed associate.

CEO hours to the bathroom during a normal work day and stays half an hour. that event right there is more than 5000

CEO makes around 11,000.00 every hour. just the top management makes around 200,000,000.00 if a quarter dividend is between 400,000,000.00 and 500,000,000.00 Just to sustain the top management is half quarter. to maintain the entire management is more than an entire quarter. Tell me what can they do to improve the company? The company is already dead before the day starts, just to be able to get those salaries. Just the CEO makes equal money to 550 employees.
Are you kidding me? When company is going to be able to get out of a crisis? Crisis for 40000 employees. not for the top management, and their lifestyles

I have them norrowed down to 2. Everytime I use their initials in a reply, it gets deleted.

Oh my, looks like someone got offended and had a post pulled. Let's try this. Google the word consultant. You bring one in to do a job your $25 an hour warm bodies can't. The consultant sets the rate, and if you can't come to an agreement they just go on to the next client. And you remain stuck with your problem. That can be kind of short sighted. Look at bec troponin. How many years and how much spent on trying to get $25 scientists to fix it? How many millions in profit lost? Or you could spend a fraction of that bringing in someone who's going to charge you a couple hundred an hour but can give you a fix for the problem in a few weeks. Course if your just playing CYA on a quarter to quarter basis ... sounds like they get what they pay for in management too.

Well 'sport' with DHR rates are going down. Is what it is.

Is there a DHR policy against bringing back "deadwood" as hired guns?

------------------------------------------------------------

Well if you got laid off at $40/hr would you go back for $25/hr?

I wouldn't hire you back because you would never be happy at $25/hr.

Layoff/R4G/downsizing/selection one way street. Move on.

Miami bleeding talent due to more frauds, and irregular procedures

Yeah folks. lot of Synergy.

We are in a hole? They don,t need people. They say that just start have a party started? Is going to be a good party!!

loved it. only the truth Biofind

"At the end of the day, rigor and commitment is going to help us get out of the hole we're in. We have done this before," Culp said about the corporate makeover under way at Beckman Coulter. "We haven't done it on this scale, but we've done it before."

Sounds like the bec associates are going to have to learn to jump through smaller and higher hoops. Funny how they keep slashing staff and the problems just keep getting worse. bec supposedly used to handle this by hiring the experts they fired to fund the management bonus as consultants to come in and solve problems that bottle washers couldnt. Is there a DHR policy against bringing back "deadwood" as hired guns?

BCI VP snitching into the forums.
Be aware of the all seeing eye. Do they trust their leaders?
Or just spying their own employees? Rumors? any rumors?

one year after??????????????

bla, bla, bla, bla, whatever.

(Substantial changes throughout with emphasis on comments about quality-control problems with Beckman Coulter's products.)

The quality problems recently identified with medical test equipment manufactured by Danaher Corp.'s DHR -0.33% Beckman Coulter unit will be fixed, but the corrections will take time and require greater commitment to accountability and standards than Beckman has shown in the past, Danaher CEO Lawrence Culp said Friday.

The U.S. Food and Drug Administration recently cited Beckman Coulter for inadequate quality controls at its California plant. The FDA said a May inspection showed the company failed to meet standards for good manufacturing practices and quality-control, particularly for a photometer-board redesign that went into production in March 2010. Beckman Coulter produces diagnostic chemistry analyzers, reagents, calibrators and controls that are used to detect diseases or other medical conditions.

Culp said the company is addressing the shortcomings raised by the FDA's inspection, but acknowledged "we have a lot of work ahead."

"We are making progress. But you have to go to the root cause," Culp said during remarks to stock analysts.

Culp said Danaher is overhauling Beckman Coulter's corporate environment to create greater discipline, accountability and simplicity at all levels of the operation. Culp said he's determined to "set a higher bar" at Beckman, which also endured the recall of a faulty test for heart problems in 2010.

"At the end of the day, rigor and commitment is going to help us get out of the hole we're in. We have done this before," Culp said about the corporate makeover under way at Beckman Coulter. "We haven't done it on this scale, but we've done it before."

Danaher's purchase of Beckman Coulter earlier this year for $5.87 billion is the largest acquisition to date for the Washington D.C. diversified manufacturer of testing, measurement and diagnostic equipment, dental equipment and water treatment systems.

By acquiring Beckman Coulter, Danaher expanded its footprint in the medical testing and diagnostics industry, which the company sees as a growth market both in the U.S. and overseas.

Besides fixing Beckman Coulter's quality problems, Culp said an aggressive restructuring of the company's cost structure is under way. Danaher aims to trim $250 million in expenses from Beckman that includes reducing the company's workforce by 1,000 positions. Rapid expansion of margins through cost reductions is a hallmark of the operating strategy that Danaher applies to all the businesses it acquires.

Culp said a less extensive restructuring also is being carried out at Danaher's other business units in response to slowing economic growth in the U.S. Culp said the moves won't affect the company's profit this year, but "positions us well for whatever may come in 2012."

"We're mindful that the environment is likely to get more challenging as we go forward," Culp said. He reiterated the company's 2011 earnings guidance from July of $2.75 to $2.82 a share.

Danaher is counting on Beckman Coulter to raise Danaher's business profile in emerging foreign markets, particularly in China. Danaher considers China a low-cost production location for exports, as well as a big domestic market for Danaher's products.

Beckman Coulter's "sales and service network are incredibly good" in China, said Jim Lico, executive vice president for Asia. "They're our biggest business there."

China accounted for about 22%, or $300 million, of Beckman Coulter's revenue in 2010. Beckman's revenue from China has been growing at a compounded annual rate of 17% for several years.

Emerging markets, which also include India, Brazil and Russia, accounted for about 20% of Danaher's revenue in 2010. Danaher has acquired nine businesses in emerging markets over the last five years and hinted that more are likely as the company tries to establish a greater presence in overseas markets with domestic brands and product lines.

Culp said rapid infrastructure construction and an expanding middle-class should drive emerging market demand for Danaher's medical technology products, testing and measurement equipment and environmental management systems.

"I'd be disappointed if we didn't see sustained double-digit growth in those businesses over the next 10 years," Culp said.

Uff! What a party! It is obnauseous

Sept. 24, 2012 (Shareholders Foundation) -- An investor in shares of IRIS International, Inc. (NASDAQ:IRIS) filed a lawsuit against directors in effort to block the proposed takeover of IRIS International at $19.50 per NASDAQ:IRIS share.

The plaintiff alleges that the defendants breached their fiduciary duties owed to NASDAQ:IRIS investors arising out of the attempt to sell the company too cheaply via an unfair process to Danaher Corporation.

On September 17, 2012, IRIS International, Inc. announced that it has entered into a merger agreement under which Danaher Corporation will acquire IRIS International for $19.50 per share in cash.

In fact, IRIS International’s performance for its investors improved lately. For instance, IRIS International, Inc. (NASDAQ:IRIS) reported that its annual Revenue rose from $95.50 million in 2008 to $118.32 million in 2011. For the second quarter 2012 IRIS International, Inc. reported an increase in its quarterly Revenue from $30.16 million last year to $30.91 million this year and its Net Loss of $0.34 million for the second quarter 2011 turned into a second quarter 2012 Net Income of $1.21 million.

Looser

Maybe. Why?

SG still in Miami?

Get ready fit the synergy. Apex style! And then venture capital . Yeah

Purple Iris can replace the SMS.

Lots of Synergy with the BCI flow and hematology folks.

1. Bring Troponin back. They had questions from the FDA regarding the temperature correction algorithms . . .
correction algorithm = assay or instrument problem hasnt been fixed
FDA should have questions
2. Obtain the intellectual property rights . . .
contract manufacturing + license payments = no profit
3. Release Vitamin D.
total vitamin D not all that relevant and immuno doesnt differentiate D2/D3
4. Release the DXN....I heard next year release to Europe
how many years have your heard that?
5. Connect the DXH's with an SMS!!!!
maybe guys with the knowhow were vested in the pension plan

Purchasing IRIS will allow Beckman to provide a larger breadth of products to laboratories. However, they need to focus on the following:
1. Bring Troponin back. They had questions from the FDA regarding the temperature correction algorithms and will need to perform additional studies. Next year release?
2. Obtain the intellectual property rights to be able to perform hepatitis and HIV on the DXi
3. Release Vitamin D.
4. Release the DXN....they are currently burning tons of money with no revenue to show yet. I heard next year release to Europe.
5. Connect the DXH's with an SMS!!!!

This year, significant progress has been made to rid themselves of the PCA issues; however, troponin is still not yet cleared.

Danaher is selling their Apex tool business to Romney's Bain Capital, having just bought Beckman Coulter after Scott Garrett was fired, and Garrett sold Dade to Bain in the 90's, and Danaher is currently buying IRIS, and now they're all rich except for the employees who lost their jobs. Technical knowledge out the door, replaced by finance. Private equity firms save America, rah rah.

technical folks over 45 better start getting there resumes out

I thought they may have had an interest in purchasing STAGO....or, are they not yet done with acquisitions?

IRIS originally had a synergistic agreement with Arkray to provide the urine dipstick reader for their IQ200 system. I'm not sure what caused the breakup and now IRIS has come out with their own dipstick system to marry with the IQ. I'm not sure about the performance of the new dipper....

Overall, I think this is a good acquisition for Danaher because IRIS' urine microscopy system is much better than the Siemens AUWI/UF100 primarily because the AUWI requires the technologist to perform a manual microscopy if there are any flags. The IRIS takes pictures so the operator can make a visual interpretation of the cell or object in question. This reduces significantly the need to stop and perform manual microscopies on urine sediment.

They are consolidating a portfolio of companies to do what they just did to Apex

Be interesting to see what product lines they keep. Lot of overlap with another acquisition they made a year or so ago.